Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 31Gynecologic 3Thoracic 1Other 1Head & Neck 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Cisplatin 27Magnetic Resonance Spectroscopy 23pembrolizumab 22Specimen Handling 19Cetuximab 17Nivolumab 14Carboplatin 13Platinum 111,2-diaminocyclohexaneplatinum II citrate 11Radiotherapy, Intensity-Modulated 10Radiotherapy 9Radiation 9Paclitaxel 8Docetaxel 8Biopsy 8Surveys and Questionnaires 6Immunoglobulin G 6Disulfides 6atezolizumab 5Ipilimumab 5Fluorouracil 5dostarlimab 4cemiplimab 4Gemcitabine 4CTLA-4 Antigen 4(225)Ac-DOTA-c(RGDyK) 4toripalimab 3relatlimab 3fludarabine 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Letrozole × Head & Neck × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡